New (Z)-and (E)-1-alkyl-3-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles and (Z)-and (E)-3(5)-(2-alkyloxyphenyl)-4-styryl-1H-pyrazoles were prepared by alkylation of (Z)-and (E)-3(5)-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles with a long chain alkyl bromide in basic medium. The affinity of these alkylated pyrazoles to both human CB1 and CB2 type cannabinoid receptors was evaluated. The results showed that some of them exhibit affinity towards CB1 cannabinoid receptors in the nanomolar range.
Introduction
Cannabinoids, the active component of marijuana  9 -THC and their analogues, exert a wide spectrum of central and peripheral effects by modulating specific CB1 and CB2 cannabinoid receptors acting as agonists, antagonists or inverse agonists. [1] [2] [3] [4] [5] Each of these activities has gained considerable attention due to their potential indication for the treatment of Alzheimer's disease, 6 obesity, epilepsy, glaucoma, motor disorders, cancer, and other pathological conditions. [7] [8] [9] [10] [11] Previous reports indicate that cannabinoids have also analgesic and anti-inflammatory properties. 12, 13 CB1 and CB2 receptors have been characterized and they are markedly different both in their distribution in the body and in their pharmacological effects. CB1 receptors are particularly abundant in the central nervous system. In contrast, the CB2 receptors are mainly found in the immune system. Both receptors belong to the family of G-protein coupled receptors and both inhibit adenylyl cyclase. [14] [15] [16] [17] The physiological roles of CB2 receptors are less know than for CB1 receptors. However, recent work is beginning to provide evidence for the role of the CB2 receptors in a number of biological functions, which include peripheral antinociception 18 and inhibition of tumour growth. [19] [20] [21] [22] A better understanding of the cannabinoid pharmacology has been possible due to the identification of endogenous ligands and the synthesis of agonists and antagonists of CB1 and CB2 receptors. 23 At present, different cannabinoid ligands have been identified, 24, 25 which can be classified into different chemical families. [27] [28] [29] [30] Among the different classes of synthetic compounds assuring CB1 or CB2 affinity and selectivity, the relevance of pyrazole derivatives has been consolidated by various studies and the pyrazole moiety is regarded as a versatile scaffold in the cannabinoid research field. [31] [32] [33] Rimonabant (SR141617A), a CB1 antagonist/inverse agonist, and its analogue SR144528, a CB2 antagonist/inverse agonist, are two examples of a large number of pyrazole analogues that have been developed. 31 Other examples are also known such as the analogous of 3-hexyl-1,5-diarylpyrazole (O-1877), 34 the AM251 (potent CB1 antagonist), 35 the novel 1,4-dihydroindeno[1,2-c]pyrazole (selective CB2 cannabinoid) and some other conformationally constrained pyrazoles. 36 The design of these pyrazoles, which are highly selective for the CB2 receptor, was based on the Sanofi CB1 and CB2 antagonists/inverse agonists, SR141716A and SR144528.
Our group have previously reported the synthesis and characterization of N-alkyl-3-and 5-(2-hydroxyphenyl)pyrazoles as potential CB1 cannabinoid ligands. 37 In order to develop additional CB1 or CB2 selective ligands and gain further insight into the SAR for these receptors, new (Z)-and (E)-1-alkyl-3-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles 3a-d and 4a-f and (Z)-and (E)-3(5)-(2-alkyloxyphenyl)-4-styryl-1H-pyrazoles 5a-d and 6a-f were prepared and assayed for binding both the brain and peripheral cannabinoid receptors. The proposed pyrazoles have some pharmacophoric elements in common with  9 -THC, namely a lipophilic side chain and a free hydroxyl group (for derivatives 3a-d and 4a-f) in an effort to study the importance of hydrogen bonds. The affinity towards the CB1-type cannabinoid receptor was evaluated in human brain tissues (frontal cortex) while the affinity towards CB2 was evaluated using membrane fractions of human CB2 receptor transfected cells. Emphasis is placed on separation of CB1 activity from CB2, since the development of compounds, which bind selectively to the CB2 receptor, could lead to potential therapeutic agents in the immune response field.
Herein we describe the synthesis, structural characterization and the evaluation of binding affinities of these new alkylpyrazoles for CB1 and CB2 receptors. 
NMR characterisation
The main features of the 1 H NMR spectra of (Z)-and (E)-1-alkyl-3-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles 3a-d and 4a-f and (Z)-and (E)-3(5)-(2-alkyloxyphenyl)-4-styryl-1H-pyrazoles 5a-d and 6a-f are: i) the triplet at H 0.86-0.88 ppm assigned to the resonance of the terminal methyl group of the alkyl chain; ii) the quintet at H 1.75-1.90 ppm due to the resonance of the protons linked to C-2 of the alkyl chain; iii) the triplet at H 3.95-4.11 ppm attributed to the resonance of the methylene group directly linked to the nitrogen or oxygen atoms; iv) the H-5 resonance appearing as a singlet or in some cases as a broad singlet at H 7.07-7.09 ppm for 3a-d, H 7.56-7.63 ppm for 4a-f, H 7.30-7.36 ppm for 5a-d and H 7.88-7.92 ppm for 6a-f; and v) the H- and H- resonances appearing as doublets or in some cases as an AB spin system at H 6.52-6.55 and 6.54-6.62 ppm for 3a-d, H 7.11-7.22 and 6.76-6.82 ppm for 4a-f, H 6.43-6.44 and 6.50-6.57 ppm for 5a-d and H 7.03-7.14 and 6.88-6.96 ppm for 6a-f. (Z)-and (E)-styrylpyrazoles can be distinguished by the coupling constant of their vinylic protons; (Z)-derivatives 3a-d and 5a-d present coupling constants of JH-H 11.8-12.0 Hz while those of (E)-derivatives 4a-f and 6a-f are JH-H 16.1-16.5 Hz.
The 1 H NMR spectra of 3a-d and 4a-f show a singlet at H 10.39-10.83 ppm due to the OH-2' proton resonance, which is absent in the spectra of compounds 5a-d and 6a-f. The high frequency value of this signal is due to an intramolecular hydrogen bond between the 2'-hydroxyl proton and N-2.
The 13 C NMR spectra of pyrazoles 3a-d, 4a-f, 5a-d and 6a-f present many signals in the aliphatic region of the spectra corresponding to the carbon resonances of the alkyl chain: i) C-1 at C 52.0-68.9 ppm the most deshielded carbon because it is directly linked to nitrogen or oxygen atoms; ii) C-2 and C-3 at respectively C 29.1-30.0 and 26.0-26.5 ppm; and iii) the signal at C 14.1 ppm assigned to the resonance of the terminal methyl group. The assignment of the other protonated carbons were made by using HSQC correlations while those of the quaternary carbons were unequivocally assigned through the connectivities found in the HMBC spectra ( Figure 1) . Some of the HMBC connectivities led to the identification of the characteristic C-3 (C 137.1-148.2 ppm), C-4 (C 114.7-118.4 ppm) and C-5 (C 129.2-139.0 ppm) pyrazolic carbons of 3a-d, 4a-f, 5a-d and 6a-f (Figure 1 ). The position of the alkyl chain of 3a-d, 4a-f, 5a-d and 6a-f was also confirmed by the connectivities found in their HMBC spectra; mainly those of the first methylene protons of the alkyl chain with those of C-5 of pyrazole ring for 3a-d and 4a-f, and those of C-2' in the case of pyrazoles 5a-d and 6a-f (Figure 1 ). The main features of the 1 H and 13 C NMR spectra of the dialkylpyrazoles 7c and 8b,e,f are the number of signals in the aliphatic region of their spectra due to the presence of two alkyl chains. The connectivities found in the HMBC spectra of these compounds also confirm the positions of the alkyl chains NCH2  C-5; H- C-5; H-6'  C-3 and OCH2  C-2'.
CB1 receptors radioligand binding assays
The pharmacological affinity for the CB1 receptors of the prepared styrylpyrazoles was evaluated through competition binding studies against the cannabinoid selective radioligand  3 HCP55-940 (1 nM). Table 2 presents the affinities of the tested compounds using SR141716A, SR144528 and AM251 as references.
In the two series of compounds 3a-d and 4a-f, the binding affinity for CB1 receptor decreased for compounds having a duodecyl chain compared to compounds having a decyl chain. For instance, 4a (Ki = 225 nM) with an alkyl chain of 10 carbons was 10 fold more affine for CB1 receptor than the analogous of 12 carbons, 4b (Ki = 2126 nM). However, this relationship is not maintained in the series 5a-d and 6a-f with the alkoxy chain of 10 or 12 carbons. Concerning the influence of the (E) and (Z) isomerism of the styryl group, compounds 4a-d with an (E)-configuration showed higher binding affinities than their corresponding analogues 3a-d having a (Z)-configuration. This relationship is not maintained in the series 5 and 6 except for 5c/6c. Except for 6c, a para-substitution (Cl or CF3) on the phenyl of the styryl group did not improve the affinity. The most potent compound 6c presents affinity in the nanomolar range (Ki = 5333 nM), being 10 fold less potent than AM251 and SR141716A respectively. This compound 6c presents an alkyl chain of 10 carbons linked to the 2'-oxygen atom. Based on this structure we pointed out that the 2'-hydroxyl group is not necessarily involved in intermolecular hydrogen bonds with CB1 receptors. Increasing the length of the alkyl chain to 12 carbons means loss of affinity.
(Z)-and (E)-1-alkyl-3-(2-alkyloxyphenyl)-4-styryl-1H-pyrazoles 7c and 8e also exhibit very low affinity for CB1 receptors. These results suggest that it is crucial to retain a structural moiety like NH or OH to establish intermolecular hydrogen bonds with CB1 receptors.
Several compounds of the new synthesized compounds exhibited micromolar affinity for the CB1 cannabinoid receptor. The best result was obtained for 6c with a Ki value of 53  33 nM.
CB2 receptors radioligand binding assays
CB2 receptor binding studies were performed according to the procedure of Griffin et al. 42 using membrane fractions of human CB2 receptor transfected cells, which ensures that only this type of receptor is present. Table 3 presents the affinities of the tested compounds using as reference WIN55,212-2 and methanandamide. The pyrazoles presented here did not show any affinity for the CB2 receptor type, except 5c, 6a and 6b that displayed low affinity for this receptor (Ki= 2000-3000 nM for CB2), however 5c and 6b were not CB2 selective (Ki= 1378 and 3279 nM respectively for CB1).
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Conclusions
An efficient way to prepare a library of new 1-alkyl-3-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles, by alkylation of 3 (5) 
Experimental Section
General. Melting points were determined on a Reichert Thermovar apparatus fitted with a microscope and are uncorrected. NMR spectra were recorded on Bruker Avance 300 (300. 13 MHz for 1 H and 75.47 MHz for 13 C) and Bruker Avance 500 (500.13 MHz for 1 H and 125.76 MHz for 13 C) spectrometers, using CDCl3 as solvent if not stated otherwise. Chemical shifts () are reported in ppm values () and coupling constants (J) in Hz. The internal standard was TMS. 1 H assignments were made using two-dimensional gradient selected correlation spectroscopy (gCOSY) and nuclear Overhauser effect spectroscopy (NOESY; 800 ms mixing time), experiments, while 13 C assignments were made using two-dimensional gradient selected heteronuclear single quantum coherence (gHSQC) and two-dimensional gradient selected heteronuclear multiple quantum coherence (gHMBC) (delays for one bond and long-range J C/H couplings were optimized for 145 and 7 Hz, respectively) experiments. Mass spectra (EI, 70 eV) were measured on a VG Autospec Q and M mass spectrometers. Positive-ion ESI mass spectra were acquired using a Q-TOF 2 instrument [diluting 1 μL of the sample chloroform or tetrahydrofuran (THF) solution (~10 -5 M) in 200 μL of 0.1% formic acid/methanol solution. Nitrogen was used as nebulizer gas and argon as collision gas. The needle voltage was set at 3000 V, with the ion source at 80°C and desolvation temperature at 150°C. Cone voltage was 35 V]. Mass spectra (MALDI TOF/TOF) were measured on a 4800 MALDI TOF/TOF Analyzer using -ciano-4-hydroxycinnamic acid as a matrix. Elemental analyses were obtained with a LECO 932 CHN analyser (University of Aveiro, Portugal). Preparative thin layer chromatography was carried out with Riedel silica gel 60 DGF254, and column chromatography using Merk silica gel 60, 70-230 mesh. All chemicals and solvents used were obtained from 4-(4-Chlorostyryl)-1-dodecyl-3-(2-hydroxyphenyl)-1H-pyrazole (4d) . Yield 83%; white solid (from ethanol); mp 65-66ºC. H (CDCl3) 0.87 3H, t, J = 6. C-3'), 115.5 (C-4), 118.2 (C-1') , 120.9 (C-5'), 121.2 (C-), 127.0 (C-4"), 128.2 (C-3",5"), 128.5 (C-2",6"), 129.4 (C-), 129.5 (C-4'), 130.3 (C-6'), 137.6 (C-3), 138.7 (C-5,1") (7), 91 (7), 69 (11) . HRMS-EI m/z for C29H37N2O 35 receptor is present. HEK293EBNA membranes were purchased from Perkin-Elmer Life and Analytical Sciences (Boston, MA). HEK293EBNA membranes were resuspended in Tris buffer (50 mM Tris-HCl, 2.5 mM EGTA, 5 mM MgCl2, 1 mg/mL BSA fatty acid free, pH 7.5).
Fractions of the final membrane suspension (about 0.18 mg/mL of protein) were incubated at 30°C for 90 min with 0.33 nM [ 3 H]-CP55-940 (139.6 Ci/mmol), in the presence or absence of several concentrations of the competing drug, in a final volume of 0.6 mL of assay buffer (50 mM Tris-HCl, 2.5 mM EGTA, 5 mM MgCl2, 1 mg/mL BSA fatty acid free, pH 7.5). Nonspecific binding was determined in the presence of 10 M WIN 55,212-2. Silanized tubes were used throughout the experiment to minimize receptor-binding loss due to tube adsorption. The reaction was terminated by rapid vacuum filtration with a filter mate Harvester apparatus (Perkin-Elmer) through Filtermat A GF/C filters pre-soaked in 0.05% polyethylenimine (PEI). The filters were washed nine times with ice-cold buffer (50 mM Tris-HCl, 2.5 mM EGTA, 5 mM MgCl2, 1 mg/mL BSA fatty acid free, pH 7.5), and bound radioactivity was measured with a 1450 LSC & Luminescence counter Wallac MicroBeta TriLux (Perkin-Elmer). The binding assay showed the appropriate sensitivity to CB2 ligands. Thus, WIN55,212-2 and methanandamide inhibited the binding with Ki values of 2.1 and 96 nM, respectively. For all binding experiments, competition binding curves were analyzed by using an iterative curvefitting procedure GraphPad (Prism), which provided IC50 values for test compounds. Ki values were determined by the method of Cheng and Prusoff. 43 Table 3 presents the affinities of the tested compounds using as reference WIN55,212-2 and methanandamide.
